Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
– Broad Distribution in CNS Demonstrated in Non-Human Primates –
– Achieved Reduction of Toxic Nuclear DMPK RNA and Foci in the Brain in a DM1 Disease Model –
Related news for (DYN)
- MoBot alert highlights: NYSE: SMRT, NASDAQ: IMAB, NASDAQ: LHAI, NASDAQ: DYN, NYSE: SGN (08/06/25 11:00 AM)
- MoBot’s Stock Market Highlights – 07/21/25 07:00 PM
- Breaking News: MoBot’s Latest Update as of 07/21/25 06:00 PM
- MoBot alert highlights: NYSE: OPAD, NASDAQ: AMIX, NASDAQ: DHAI, NASDAQ: OPEN, NASDAQ: DYNXW (07/21/25 11:00 AM)
- Stocks Taking Flight: Lux Entertainment, Crypto, and Capital Push New Frontiers